Novartis wouldn't be telling porky pies and misleading the market would they?
Most likely given they don't generally treat children under 12 years of age for sr-GVHD so their interpretations might be a little askew in some way ? Let's see their comparisons for 4 year survival data shall we ... oh wait .. they don't have any for this cohort <12 yo ... and the adult cohort seems to struggle as well for great long term survival - just sayin'
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)